Purine and purinergic receptors in health and disease.
ATP
P2x7
cancer
immunity
purinergic
tumor microenvironment
Journal
MedComm
ISSN: 2688-2663
Titre abrégé: MedComm (2020)
Pays: China
ID NLM: 101769925
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
28
03
2023
revised:
07
08
2023
accepted:
10
08
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Purines and purinergic receptors are widely distributed throughout the human body. Purine molecules within cells play crucial roles in regulating energy metabolism and other cellular processes, while extracellular purines transmit signals through specific purinergic receptors. The ubiquitous purinergic signaling maintains normal neural excitability, digestion and absorption, respiratory movement, and other complex physiological activities, and participates in cell proliferation, differentiation, migration, and death. Pathological dysregulation of purinergic signaling can result in the development of various diseases, including neurodegeneration, inflammatory reactions, and malignant tumors. The dysregulation or dysfunction of purines and purinergic receptors has been demonstrated to be closely associated with tumor progression. Compared with other subtypes of purinergic receptors, the P2X7 receptor (P2X7R) exhibits distinct characteristics (i.e., a low affinity for ATP, dual functionality upon activation, the mediation of ion channels, and nonselective pores formation) and is considered a promising target for antitumor therapy, particularly in patients with poor response to immunotherapy This review summarizes the physiological and pathological significance of purinergic signaling and purinergic receptors, analyzes their complex relationship with tumors, and proposes potential antitumor immunotherapy strategies from tumor P2X7R inhibition, tumor P2X7R overactivation, and host P2X7R activation. This review provides a reference for clinical immunotherapy and mechanism investigation.
Identifiants
pubmed: 37692109
doi: 10.1002/mco2.359
pii: MCO2359
pmc: PMC10484181
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e359Informations de copyright
© 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Discov. 2021 Jun;11(6):1353-1367
pubmed: 33712487
Oncoscience. 2015 Aug 30;2(8):673-4
pubmed: 26425653
CNS Neurol Disord Drug Targets. 2017;16(3):257-265
pubmed: 27658510
Cancer Res. 2012 Nov 1;72(21):5441-7
pubmed: 23090120
Vasc Cell. 2013 Dec 06;5(1):20
pubmed: 24314323
Expert Opin Ther Pat. 2010 May;20(5):625-46
pubmed: 20205618
Purinergic Signal. 2013 Dec;9(4):491-540
pubmed: 23797685
Br J Pharmacol. 1970 Dec;40(4):668-88
pubmed: 4322041
Cancer Res. 2015 Feb 15;75(4):635-44
pubmed: 25542861
Biochem Biophys Res Commun. 2010 Jan 1;391(1):498-504
pubmed: 19919827
Anticancer Res. 2010 Jul;30(7):2823-30
pubmed: 20683018
PLoS One. 2014 Dec 08;9(12):e114371
pubmed: 25486274
Clin Immunol. 2018 Mar;188:67-73
pubmed: 29274390
Stem Cell Rev Rep. 2020 Apr;16(2):288-300
pubmed: 31813120
Expert Opin Investig Drugs. 2011 Jul;20(7):897-915
pubmed: 21510825
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
Am J Cardiovasc Drugs. 2019 Oct;19(5):449-464
pubmed: 30972618
Carcinogenesis. 2011 Aug;32(8):1167-75
pubmed: 21642357
Biochem Pharmacol. 2018 May;151:234-244
pubmed: 29288626
Pain. 1995 Oct;63(1):65-76
pubmed: 8577492
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
PLoS One. 2013 Aug 05;8(8):e70577
pubmed: 23940597
Cell Death Dis. 2014 Mar 20;5:e1135
pubmed: 24651438
Mol Biol Cell. 2005 Jul;16(7):3260-72
pubmed: 15901833
J Med Chem. 2016 Aug 25;59(16):7410-30
pubmed: 27427902
Pulm Pharmacol Ther. 2019 Jun;56:56-62
pubmed: 30902655
Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592
pubmed: 28683172
J Physiol. 1977 Jun;268(2):371-90
pubmed: 141503
Br J Pharmacol. 2020 Jun;177(11):2413-2433
pubmed: 32037507
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22862-22871
pubmed: 31636190
J Immunol. 2010 Aug 15;185(4):2611-9
pubmed: 20639492
PLoS One. 2014 Oct 31;9(10):e111385
pubmed: 25360548
Eur J Pharmacol. 2010 Aug 25;640(1-3):15-9
pubmed: 20452342
Curr Med Chem. 2015;22(7):866-77
pubmed: 25524252
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2307-15
pubmed: 26359511
Curr Opin Pharmacol. 2019 Aug;47:33-39
pubmed: 30878800
FEBS Lett. 1999 Mar 19;447(1):71-5
pubmed: 10218585
Int J Mol Sci. 2022 Jan 22;23(3):
pubmed: 35163142
PLoS One. 2008 Jul 09;3(7):e2599
pubmed: 18612415
J Thromb Haemost. 2015 Jun;13 Suppl 1:S10-6
pubmed: 26149010
Oncol Rep. 2009 Apr;21(4):977-81
pubmed: 19287996
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
Eur J Pharmacol. 2012 Nov 15;695(1-3):20-6
pubmed: 22981895
Immunol Lett. 2019 Jan;205:16-24
pubmed: 30439478
Purinergic Signal. 2019 Sep;15(3):367-374
pubmed: 31401785
Front Mol Neurosci. 2019 Aug 07;12:183
pubmed: 31440138
Int J Mol Sci. 2020 Jun 03;21(11):
pubmed: 32503307
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Immunol. 2006 Apr 1;176(7):3877-83
pubmed: 16547218
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Immunol Rev. 2017 Nov;280(1):83-92
pubmed: 29027229
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Int J Mol Sci. 2023 Jun 30;24(13):
pubmed: 37446075
Br J Haematol. 2013 Aug;162(3):313-25
pubmed: 23691926
Nat Commun. 2022 Nov 2;13(1):6578
pubmed: 36323669
Prog Med Chem. 2020;59:63-99
pubmed: 32362329
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Pharmacol Rev. 2022 Apr;74(2):340-372
pubmed: 35302044
Nat Rev Cancer. 2023 May;23(5):275-294
pubmed: 36973407
Exp Physiol. 2022 Apr;107(4):350-358
pubmed: 35165960
J Neurosci. 2010 Oct 20;30(42):14213-24
pubmed: 20962242
J Thromb Haemost. 2020 Jan;18(1):44-56
pubmed: 31448510
J Cell Biochem. 2019 Apr;120(4):6322-6329
pubmed: 30362154
J Immunol. 2017 Jul 1;199(1):72-81
pubmed: 28515278
Biomed Pharmacother. 2021 Sep;141:111824
pubmed: 34175815
Expert Opin Ther Pat. 2017 Mar;27(3):257-267
pubmed: 27724045
Curr Med Chem. 2011;18(8):1164-87
pubmed: 21291368
Cancer Cell Int. 2019 Oct 01;19:254
pubmed: 31582910
Cancer Immunol Res. 2020 Nov;8(11):1426-1439
pubmed: 32933967
Cell Microbiol. 2012 Nov;14(11):1697-706
pubmed: 22882764
Cancer Lett. 2008 Feb 18;260(1-2):79-87
pubmed: 18039556
Curr Opin Pharmacol. 2016 Aug;29:17-25
pubmed: 27262778
Mol Cancer. 2015 Nov 25;14:203
pubmed: 26607222
J Clin Invest. 2002 Oct;110(7):993-1002
pubmed: 12370277
Oncotarget. 2015 Dec 1;6(38):41162-79
pubmed: 26517690
Platelets. 2021 Oct 3;32(7):902-908
pubmed: 33760688
Physiol Rev. 2007 Apr;87(2):659-797
pubmed: 17429044
Annu Rev Physiol. 2019 Feb 10;81:43-62
pubmed: 30354932
Sci Rep. 2019 Dec 12;9(1):18938
pubmed: 31831761
J Mol Med (Berl). 2021 Mar;99(3):349-358
pubmed: 33486566
J Cell Physiol. 2020 Dec;235(12):9676-9690
pubmed: 32420639
Adv Exp Med Biol. 2017;1051:139-168
pubmed: 28815513
Histopathology. 2004 Mar;44(3):206-15
pubmed: 14987223
Purinergic Signal. 2014;10(2):313-26
pubmed: 24163006
Int J Mol Sci. 2020 Jul 14;21(14):
pubmed: 32674494
Theranostics. 2022 Jan 1;12(2):859-874
pubmed: 34976217
Gene. 2018 May 15;654:95-102
pubmed: 29408621
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6
pubmed: 23964122
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Bioessays. 2014 Jul;36(7):697-705
pubmed: 24782352
Biochem Pharmacol. 2021 May;187:114322
pubmed: 33161020
Hematol Oncol. 2012 Jun;30(2):70-5
pubmed: 21812012
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Signal Transduct Target Ther. 2021 Apr 28;6(1):162
pubmed: 33907179
Int J Mol Sci. 2020 Aug 03;21(15):
pubmed: 32756482
Cancer Res. 2012 Jun 15;72(12):2957-69
pubmed: 22505653
Immunity. 2020 Feb 18;52(2):357-373.e9
pubmed: 32049051
Cancer Res. 2015 Mar 1;75(5):835-45
pubmed: 25564520
Int J Cancer. 2007 Jul 1;121(1):55-65
pubmed: 17330843
Cells. 2020 Mar 24;9(3):
pubmed: 32213945
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16788-93
pubmed: 19805374
Oncogene. 2011 May 5;30(18):2108-22
pubmed: 21242969
J Clin Invest. 1995 Mar;95(3):1207-16
pubmed: 7883969
Methods Mol Biol. 2020;2041:183-195
pubmed: 31646489
Nat Commun. 2017 Jan 27;8:13772
pubmed: 28128211
J Neurosci. 2015 May 20;35(20):7950-63
pubmed: 25995479
J Med Chem. 2022 Dec 8;65(23):15967-15990
pubmed: 36394994
Cell Cycle. 2009 Nov 15;8(22):3723-8
pubmed: 19855167
Immunity. 2015 Nov 17;43(5):923-32
pubmed: 26572062
J Cell Biochem. 2010 Apr 1;109(5):983-91
pubmed: 20069573
Front Pharmacol. 2017 Nov 14;8:821
pubmed: 29204116
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
BMC Cancer. 2015 Jul 31;15:563
pubmed: 26228921
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
Br J Pharmacol. 2001 Jan;132(2):536-46
pubmed: 11159704
Annu Rev Immunol. 2019 Apr 26;37:325-347
pubmed: 30676821
J Oncol. 2012;2012:608406
pubmed: 22927846
Blood. 2006 Jun 15;107(12):4946-53
pubmed: 16514055
Physiol Rev. 2002 Oct;82(4):1013-67
pubmed: 12270951
Blood. 2002 Jan 15;99(2):706-8
pubmed: 11781259
Cells. 2020 Jul 03;9(7):
pubmed: 32635260
Biochem Pharmacol. 2021 May;187:114408
pubmed: 33444568
Front Cell Dev Biol. 2022 May 18;10:876510
pubmed: 35663396
Sci Am. 2009 Dec;301(6):84-90, 92
pubmed: 20058644
Eur J Pharmacol. 2004 Nov 3;504(1-2):45-53
pubmed: 15507220
BMB Rep. 2018 Sep;51(9):468-473
pubmed: 30103845
J Biol Chem. 1999 Nov 19;274(47):33206-8
pubmed: 10559192
Cell. 2022 Feb 3;185(3):576
pubmed: 35120665
Clin Immunol Immunopathol. 1993 Feb;66(2):91-106
pubmed: 8453790
Oncotarget. 2017 Jul 25;8(30):48755-48768
pubmed: 28548944
Endocrinology. 2008 Jan;149(1):389-96
pubmed: 17947359
Oncogene. 2015 Oct 8;34(41):5240-51
pubmed: 25619831
Purinergic Signal. 2021 Mar;17(1):117-125
pubmed: 33336318
Cancer Res. 2020 Feb 15;80(4):699-708
pubmed: 31822494
Circ Res. 2002 Mar 22;90(5):531-8
pubmed: 11909816
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Purinergic Signal. 2016 Sep;12(3):439-51
pubmed: 27020575
Cell Death Dis. 2021 Nov 16;12(12):1088
pubmed: 34789738
Cell Signal. 2009 Jun;21(6):881-91
pubmed: 19385050
PLoS One. 2013 Dec 02;8(12):e80707
pubmed: 24312495
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
Cell Death Differ. 2023 Feb;30(2):429-441
pubmed: 36450825
Cell Death Dis. 2012 Aug 16;3:e370
pubmed: 22898868
Cell Death Dis. 2020 Oct 18;11(10):876
pubmed: 33071281
Eur J Pharmacol. 2021 Oct 5;908:174344
pubmed: 34270987
PLoS One. 2016 Mar 10;11(3):e0151420
pubmed: 26964090
J Physiol. 1929 Nov 25;68(3):213-37
pubmed: 16994064
Proteins. 2022 Oct;90(10):1779-1785
pubmed: 35023590
Sci Rep. 2017 Mar 15;7(1):196
pubmed: 28298636
Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Apr 18;49(2):188-195
pubmed: 28416823
Biochem Pharmacol. 2010 May 15;79(10):1483-95
pubmed: 20096265
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Biochem Pharmacol. 2021 May;187:114361
pubmed: 33309519
Pharmacol Ther. 2006 Nov;112(2):358-404
pubmed: 16784779
Front Pharmacol. 2017 Sep 25;8:661
pubmed: 28993732
PLoS One. 2018 Sep 24;13(9):e0204229
pubmed: 30248132
Endocrinology. 2011 Oct;152(10):3706-16
pubmed: 21828185
Cancers (Basel). 2023 Jan 18;15(3):
pubmed: 36765547
Front Pharmacol. 2020 Jun 04;11:793
pubmed: 32581786
Mol Cell Oncol. 2015 Feb 03;3(2):e1010937
pubmed: 27308580
J Exp Clin Cancer Res. 2016 Oct 3;35(1):161
pubmed: 27716441
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Eur J Pharmacol. 2012 Aug 5;688(1-3):27-34
pubmed: 22634164
Purinergic Signal. 2023 Jun;19(2):441-450
pubmed: 36400869
Brain Neurosci Adv. 2018 Dec 6;2:2398212818817494
pubmed: 32166165
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Biochim Biophys Acta. 2011 May;1808(5):1400-12
pubmed: 20888788
Purinergic Signal. 2014 Sep;10(3):487-97
pubmed: 24627191
Biochem Pharmacol. 2021 May;187:114319
pubmed: 33161021
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1539-1551
pubmed: 29454075
Nat Med. 2015 Aug;21(8):846-53
pubmed: 26248267
Curr Opin Pharmacol. 2017 Dec;37:131-141
pubmed: 29149731
J Physiol. 1972 Aug;224(3):611-28
pubmed: 5071932
Purinergic Signal. 2021 Jun;17(2):215-227
pubmed: 33728582
Cancer Res. 2011 Apr 15;71(8):2892-900
pubmed: 21292811
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
CNS Neurol Disord Drug Targets. 2012 Sep;11(6):722-38
pubmed: 22963441
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Br J Pharmacol. 2021 Feb;178(3):489-514
pubmed: 33125712
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Neurobiol Dis. 2005 Feb;18(1):100-9
pubmed: 15649700
Pharmacol Rev. 1972 Sep;24(3):509-81
pubmed: 4404211
PLoS One. 2015 Jul 16;10(7):e0133165
pubmed: 26182292
Oncotarget. 2016 May 17;7(20):29036-50
pubmed: 27074554
Br J Dermatol. 2017 Jul;177(1):117-124
pubmed: 28150889
Arch Biochem Biophys. 2010 Feb 1;494(1):7-14
pubmed: 19900397
Front Immunol. 2017 Dec 22;8:1918
pubmed: 29312358
Neoplasia. 2009 Nov;11(11):1132-45
pubmed: 19881949
Front Pharmacol. 2021 Jan 27;11:617211
pubmed: 33584298
J Exp Clin Cancer Res. 2019 Jun 3;38(1):233
pubmed: 31159832
Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1024-35
pubmed: 15662049
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):186-199
pubmed: 32998520
Pharmacol Rev. 2006 Mar;58(1):58-86
pubmed: 16507883
Purinergic Signal. 2019 Jun;15(2):155-166
pubmed: 31016551
Purinergic Signal. 2009 Sep;5(3):351-68
pubmed: 19399640
Purinergic Signal. 2009 Jun;5(2):251-6
pubmed: 19263244
Nature. 2014 Apr 3;508(7494):24-6
pubmed: 24695297
Blood. 2001 Feb 1;97(3):587-600
pubmed: 11157473
Oncogene. 2019 May;38(19):3636-3650
pubmed: 30655604
Oncotarget. 2016 Aug 2;7(31):49664-49676
pubmed: 27391069
J Theor Biol. 1976 Oct 21;62(2):491-503
pubmed: 994531
Int J Mol Sci. 2020 Aug 20;21(17):
pubmed: 32825423
J Clin Invest. 2011 Oct;121(10):3804-9
pubmed: 21965337
Recent Pat DNA Gene Seq. 2011 Apr;5(1):41-54
pubmed: 21303345
Purinergic Signal. 2020 Sep;16(3):347-366
pubmed: 32638267
Eur J Pharmacol. 2021 May 15;899:174041
pubmed: 33737010
Biochem Pharmacol. 2021 May;187:114405
pubmed: 33406411
Circulation. 2011 May 31;123(21):2404-13
pubmed: 21576651
J Invest Dermatol. 2003 Aug;121(2):315-27
pubmed: 12880424
J Pain Symptom Manage. 2022 Mar;63(3):e317-e335
pubmed: 34563628
Mol Biol Rep. 2018 Dec;45(6):2625-2630
pubmed: 30343397
Cancer Lett. 2016 Jan 1;370(1):85-90
pubmed: 26477683
Cells. 2019 Dec 29;9(1):
pubmed: 31905754
Cell Reprogram. 2021 Apr;23(2):57-72
pubmed: 33861641
Sci Rep. 2016 Sep 02;6:32602
pubmed: 27586846
Nat Med. 2010 Dec;16(12):1434-8
pubmed: 21102458
Science. 1996 May 3;272(5262):735-8
pubmed: 8614837
Mol Cancer. 2017 Jun 7;16(1):99
pubmed: 28592285
Oncotarget. 2015 Sep 29;6(29):27478-89
pubmed: 26317647
Oncoimmunology. 2018 Apr 18;7(8):e1452579
pubmed: 30221045
Biochem Biophys Res Commun. 1996 Apr 25;221(3):588-93
pubmed: 8630005